Key result
TAVI increased high-degree AV block (0% to 9.1%, p=0.004) and AF (16% to 25%, p=0.035), while decreasing daily NSVT rate (0.2 to 0.1 episodes/24h, p<0.001) on paired 14-day ECG monitoring.
Why the study?
Therapeutic management after TAVI requires precise rhythm risk stratification, yet intra-individual data quantifying qualitative and quantitative rhythm changes both before and after the intervention remained limited.
How does transcatheter aortic valve implantation affect intra-individual arrhythmia incidence and quantitative rhythm dynamics on paired 14-day ambulatory ECG monitoring?
Observational (n=100)
How does transcatheter aortic valve implantation affect intra-individual arrhythmia incidence and quantitative rhythm dynamics on paired 14-day ambulatory ECG monitoring?
Paired 14-day ECG monitoring before and after TAVI demonstrates a dual electrophysiological impact, increasing conduction disturbances and new-onset atrial fibrillation while reducing the frequency and duration of pre-existing non-sustained ventricular tachycardia.
TAVI was associated with increased high-degree AV block and AF but reduced NSVT on paired monitoring; leaves open whether these changes warrant routine extended surveillance.
Introduction Therapeutic management after transcatheter aortic valve implantation (TAVI) requires precise rhythm risk stratification. While prior studies have described arrhythmias either before or after TAVI, intra-individual data quantifying qualitative and quantitative rhythm changes across the intervention remain limited. Purpose We aimed to characterize paired arrhythmia dynamics using extended ambulatory ECG monitoring before and after TAVI. Methods Consecutive patients undergoing TAVI were prospectively enrolled if 14-day ambulatory ECG patch monitoring was available both before and after the procedure. Paired intra-individual analyses were performed to evaluate changes in arrhythmia incidence as well as quantitative parameters, including arrhythmia burden, longest episode duration, and daily episode rate. Results Paired 14-day ECG monitoring was available in 100 patients (median age 82 years [78–85], 43% female), with comparable analyzable durations before and after TAVI. Following TAVI, the incidence of high-degree atrioventricular block (HAVB) increased from 0% to 9.1% (p=0.004), accompanied by significant increases in HAVB episode rate and burden (both p=0.009). Atrial fibrillation (AF) occurrence increased from 16% to 25% (p=0.035). Among patients with AF pre- or post-TAVI, AF burden increased significantly (median 0.4% vs. 18.3%, p=0.026). However, in patients with pre-existing AF (n=16), the longest AF episode was significantly shorter after TAVI (median 179.5 h vs. 50.8 h, p=0.041), with no significant change in AF burden. In contrast, ventricular arrhythmias showed improvement in patients with pre-existing non-sustained ventricular tachycardia (NSVT, n=55). Daily NSVT episode rate decreased (median 0.2 vs. 0.1 episodes/24h, p<0.001), together with a reduction in longest NSVT episode duration (median 3.0 s vs. 2.6 s, p=0.012). Supraventricular or ventricular ectopy did not change significantly in paired analyses. Conclusion Paired extended ECG monitoring reveals divergent electrophysiological effects of TAVI. While conduction disturbances and AF increase post-procedure, NSVT frequency and arrhythmia persistence decrease in patients with pre-existing tachyarrhythmias. These findings suggest simultaneous pro-arrhythmic effects on the conduction system and potentially anti-arrhythmic effects through hemodynamic unloading, underscoring the need for individualized rhythm surveillance after TAVI.
No takes yet. Share an insight, caveat, or question.
Moser et al. (2026) conducted an observational in Transcatheter aortic valve implantation (TAVI) (n=100). Transcatheter aortic valve implantation (TAVI) vs. Pre-TAVI baseline (paired intra-individual comparison) was evaluated on High-degree atrioventricular block (HAVB) incidence (p=0.004). TAVI increased high-degree AV block (0% to 9.1%, p=0.004) and AF (16% to 25%, p=0.035), while decreasing daily NSVT rate (0.2 to 0.1 episodes/24h, p<0.001) on paired 14-day ECG monitoring.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: